Inclusion Criteria (Key Factors):

          1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or
             more of the following:

               1. Patient is intolerant of existing therapy(ies) known to provide clinical benefit
                  for their condition

               2. Malignancy is refractory to existing therapy(ies) known to potentially provide
                  clinical benefit

               3. Malignancy has progressed after standard therapy

          2. Has evaluable or measurable tumor(s) in dose escalation by standard radiological
             and/or laboratory assessments as applicable to their malignancy.

          3. Eastern Co-operative Oncology Group (ECOG) PS 0-1

        Exclusion Criteria (Key Factors):

          1. Receiving cancer treatment at the time of enrollment

          2. Any clinically significant disease or condition affecting a major organ system

          3. Significant cardiovascular disease or electrocardiogram (ECG) abnormalities

          4. Use of a strong inhibitor or inducer of CYP3A4 within 7 days prior to start of study
             therapy and throughout the study (e.g., some antibiotics, antifungals,
             anticonvulsants, grapefruit)

          5. Has had a previous (within 2 years) or has a current malignancy other than the target
             cancer